Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies KRAS mutation as a biomarker of poor prognosis.

Ying DingYang ShaoChenglong NaJiani C YinHongjin HuaRan TaoYue JiangRan HuXiao HeChen MiaoDongqin ZhuZhi-Hong Zhang

Published in: Journal of medical genetics (2020)

Taken together, our results suggest that comprehensive genetic testing may be necessary to inform treatment options and identify prognostic biomarkers.

Keyphrases

poor prognosis
genome wide
long non coding rna
dna methylation
high grade
copy number
wild type
gene expression